Theaflavin-3,3′-Digallate Inhibits Erasin-Induced Chondrocytes Ferroptosis via the Nrf2/GPX4 Signaling Pathway in Osteoarthritis

Chao Xu,1 Su Ni,2 Nanwei Xu,3 Guangrong Yin,4 Yunyuan Yu,5 Baojun Zhou,6 Gongyin Zhao,3 Liangliang Wang,3 Ruixia Zhu,3 Shijie Jiang,3 and Yuji Wang3,6,7

1Truma Central, The Affiliated Changzhou No.2 People’s Hospital with Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China
2Medical Research Center, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China
3Department of Orthopedics, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou Second People’s Hospital, Changzhou Medical Center, Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China
4Graduate School of Dalian Medical University, 9 West Section, Shunnan Road, Dalian 116044, China
5The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China
6Department of Orthopedics, The Third Affiliated Hospital of Gansu University of Chinese Medicine, 222 Silong Road, Baiyin 730900, China
7Department of Orthopedic Surgery and Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN, USA

Correspondence should be addressed to Yuji Wang; 13775221377@139.com

Received 15 June 2022; Revised 20 October 2022; Accepted 1 November 2022; Published 17 November 2022

Academic Editor: Demetrios Kouretas

There is evidence that osteoarthritis (OA) is associated with ferroptosis which is a kind of lipid peroxidation-related cell death. Theaflavin-3,3′-digallate (TF3), a polyphenol compound extracted from black tea, possesses antioxidative and anti-inflammatory properties, but its effects on chondrocyte ferroptosis in osteoarthritis (OA) remain unclear. Our present study aims at exploring the protective role and underlying mechanisms of TF3 against erasin-induced chondrocyte ferroptosis in OA. In human primary chondrocytes treated with erasin alone or combined with different doses of TF3, cell viability was assessed by MTS. Ferroptosis-related proteins, including Gpx4, HO-1, and FTH1, were detected by western blot. The levels of lipid peroxidation and Fe2+ were determined by fluorescence staining. Meanwhile, the change of related proteins in the Nrf2/Gpx4 signaling pathway was determined by western blot. siRNA-mediated Nrf2 knockdown and the Gpx4 inhibitor RSL3 were used to explore molecular mechanisms for TF3-induced ferroptosis in OA chondrocyte. The magnetic resonance imaging (MRI), HE staining, Masson’s staining, and immunohistochemistry were used to evaluate articular cartilage damages in the rat OA model. The results showed that Gpx4 expression was markedly downregulated in the chondrocytes of OA patients. TF3 reversed erasin-induced ferroptosis of human cultured chondrocytes, lipid ROS, and Fe2+ production in mitochondria. Moreover, the expression of Gpx4, HO-1, FTH1, and Nrf2 was markedly induced by TF3 in the erasin-treated chondrocytes. The antiferroptotic effect of TF3 was related to enhance Nrf2/Gpx4 signaling pathway. Finally, TF3 inhibited OA progression by alleviating in vivo cartilage damage related to chondrocyte ferroptosis. Thus, TF3 significantly inhibits chondrocyte ferroptosis by activating the Nrf2/Gpx4 signaling pathway, suggesting that TF3 serves as a potential therapeutic supplement for OA treatment.
1. Introduction

Osteoarthritis (OA), a chronic degenerative disease, has become a notable cause of disability in elderly patients. The incidence of OA among people over 75 years old is approximately 70% to 90%, and more than 100 million people worldwide suffer from OA [1]. The clinical manifestations of OA are joint pain, swelling, joint deformities, and restricted mobility [2]. Cartilage degeneration, destruction, and osteophyte formation are the main pathological features of OA [2]. Many physiological processes contribute to the development of OA, such as pyroptosis, apoptosis, and autophagy of chondrocytes. Chondrocytes undergo ferroptosis during OA, and that ferroptosis contributes to the progression of the disease [3]. Thus, inhibition of chondrocyte ferroptosis promises a potential OA therapy.

Ferroptosis is a type of iron-dependent lipid peroxidation-related cell death process that requires the accumulation of iron-dependent cellular active oxidation products [4]. Ferroptosis can lead to the progression of various diseases, including ischemia–reperfusion injury [5], neurodegenerative diseases [6], and tumors [7]. Iron is essential for cell physiological and biochemical processes, including participation in oxygen transport, DNA and ATP synthesis, and the tricarboxylic acid (TCA) cycle [8, 9]. In addition, Fe^{2+} promotes the lipid peroxidation of saturated fatty acids and the oxidative phosphorylation of mitochondria [10, 11]. The oxidative reaction induced by iron deposition leads to oxidative stress, causing protein, nucleic acid, and liposome damage directly or indirectly, which gives rise to cell damage or ferroptosis [12]. Firstly, liposome peroxidation causes damage to cell membrane composition and structure [13, 14]. In addition, liposome peroxidation produces a large amount of lethal reactive oxygen species (ROS), malondialdehyde (MDA), and peroxide dismutase (SOD), and these products can react with DNA or protein, further exerting toxic effects [15]. Glutathione peroxidase 4 (Gpx4), a lipid repair enzyme, is regulated by glutathione (GSH), which has been illustrated to block ferroptosis by reducing lipid peroxidation products and lethal reactive oxygen species accumulation [16, 17]. Activation of the antioxidant enzyme Gpx4 may have a potential to suppress ferroptosis.

Theaflavin-3′,3′-digallate (TF3), a polyphenol compound extracted from black tea [18], has attracted medical attention because of its extensive pharmacological effects, such as anticancer, antiviral, antioxidant, and anti-inflammatory [19], and immunomodulatory [20] effects. A previous study indicates that TF3 regulates the expression of copper transporter 1 that TF3 inhibits RANKL-induced osteoclast formation in bone marrow-derived macrophages (BMMs) in animal models [23]. In addition, TF3 could activate plasma kallikrein expression, reduce the deposition of fat and antagonize the oxidative damage induced by H_2O_2 in hepatocytes [24]. In human chondrocytes, theaflavins (TFs) reduced oxidative stress-induced apoptosis and modulated AKT activation [25]. Moreover, ferroptosis is affected by multiple signaling pathways in cells [26]. The Keap1/Nrf2 pathway is involved in glioma cell proliferation and ferroptosis [27]. MAPK/ERK/p38 [28, 29], Stat3/Nrf2/Gpx4 [30, 31], and ALK4/5 [32] signaling pathways are critical for ferroptosis induction. Despite these exciting discoveries, it remains that the role of TF3 in OA chondrocyte ferroptosis and related signaling pathway is far from elucidated. In this study, we aimed to further explore the role of TF3 in OA chondrocyte ferroptosis and elucidate its underlying mechanisms.

2. Materials and Methods

2.1. Collection of Subjects. Informed consent was received from all individual participants (including OA patients and trauma patients with femur fractures) in this study, and the sample (cartilage tissue) collection was approved by the Medical Ethical Committee of Changzhou No. 2. People’s Hospital.

2.2. Reagents. TF3 was purchased from Shanghai YuanYe Bio-tech. Co., Ltd. (Shanghai, China), with an approximate purity of 98%. TF3 was dissolved in ethyl alcohol and diluted with DMEM/F12 for experiments. Collagenase II (Worthington Biochemical Corp., Lakewood, NJ, USA) was dissolved in DMEM at 2.5 mg/ml to digest the articular cartilage. Erastin, a ferroptosis activator acting on mitochondrial voltage-dependent anion channels (VADC), was purchased from Sigma–Aldrich, reconstituted in DMSO at 5 mM and stored at -20°C in the darkness. RSL3, a Gpx4 inhibitor, and deferoxamine (DFO), a ferroptosis inhibitor, were purchased from Selleckchem (Houston, TX, USA).

2.3. Isolation and Culture of Human Chondrocytes. Cartilage tissue specimens were obtained from the medial condyle (severely damaged joint areas) of the femur of OA patients and trauma patients with femur fracture during joint replacement surgery in the Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University. The OA severity was determined using weight-bearing anteroposterior radiographs of the affected joints according to the Kellgren and Lawrence (KL) classification (all the KL classification of all OA patients was at grade 3 in our study). These female patients with femur fractures had healthy joints. The clinical characteristics (age, gender, and disease duration) of all participants were shown in Table 1. All articular cartilage tissues were carefully minced and digested with collagenase II in serum-free Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL, Grand Island, NY, USA), filtered through a 70 μm cell strainer (BD, Durham, NC, USA), and extensively washed with blank DMEM/F12. Finally, chondrocytes were cultured in DMEM/F12 containing 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA), 50 μg/mL ascorbic acid (AA, Sigma), 100 U of penicillin, and 100 μg/mL streptomycin. When adherent cell confluence reached 90%, chondrocytes were separated. Passages 2 to 3 were used in our experiments.

2.4. MTS Cytotoxicity Assays. MTS (Promega, Madison, WI, USA) cytotoxicity assays were applied to assess human OA chondrocyte cytotoxicity and viability. A total of 5 × 10^3 cells were plated in 96-well plate and allowed to attach
Table 1: Characteristic of subjects investigated.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>OA</th>
<th>TRUMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of subjects</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Age, years</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>25th percentile</td>
<td>62</td>
<td>61</td>
</tr>
<tr>
<td>75th percentile</td>
<td>72</td>
<td>70</td>
</tr>
<tr>
<td>Number of female/male subjects</td>
<td>20/0</td>
<td>20/0</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>4.8</td>
<td>—</td>
</tr>
<tr>
<td>25th percentile</td>
<td>2.5</td>
<td>—</td>
</tr>
<tr>
<td>75th percentile</td>
<td>6.5</td>
<td>—</td>
</tr>
</tbody>
</table>

Median.

overnight. TF3 and erastin were used to treat chondrocytes. After treatment, 10 μl of MTS solution reagent was pipetted into each well of a 96-well plate. Then, the plate was incubated at 37°C for 2 hours without light, and the absorbance at 490 nm was recorded with an absorbance microplate reader (Elx808™ Bio-Tek Instruments, Winooski, VT).

2.5. RT–PCR Analysis. Chondrocytes were treated in different conditions, and then total RNA was extracted with the NucleoSpin RNA Kit (MN, Düren, Germany) according to the instructions. After the obtained RNA was quantified, 1 μg of total RNA was taken, and reverse transcription was performed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the instructions. SYBR® Select Master Mix (Applied Biosystems, Austin, TX, USA) was used to perform quantitative PCR to detect Gpx4 mRNA expression in chondrocytes, and GAPDH was selected as the internal reference. The specific primer sequences were designed by Shenggong Biotech. Co., Ltd. (Shanghai, China) and are as follows: Gpx4, 5′-GGGCGAGCCC-GAAGTAAACTAC-3′ (forward) and 5′-CCGAACTGTTACACGGGAA-3′ (reverse); GAPDH, 5′-CTGGGCTACACCCCATGGACC-3′ (forward) and 5′-AAGTGGTCGTTGAGGGCAATG-3′ (reverse). Quantitative PCR was performed using the ViiA™ 7 real-time PCR system. The comparative threshold cycle method was used to determine the relative quantification of mRNA.

2.6. Western Blot Analysis. Cultured chondrocytes were lysed on ice with RIPA buffer (Beyotime Biotechnology, Shanghai, China) and boiled for 5 min at 99°C. A 15% polyacrylamide gel was used to separate proteins, and then proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore Corp., Danvers, MA, USA). The following rabbit polyclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA), ABclonal Technology (Wuhan, China), and Proteintech (Wuhan, China). The information of antibodies is listed in Table S1. Rabbit polyclonal antibodies were used to detect human proteins related to the Nrf2/Gpx4 signaling pathways and ferroptosis-related proteins Slc7a11, FTH1, and HO-1. The human β-actin antibody was used as an internal control.

2.7. Propidium Iodide Stain. After different treatments, 2 μl of PI solution reagent (Vazyme Biotech Co., Ltd., Nanjing, China) was pipetted into each well plate. Then, the plate was incubated at room temperature for 5 minutes without light and was observed under a fluorescence microscope (Nikon Eclipse Ti, Japan).

2.8. Nuclear Protein Extraction. Nuclear protein was extracted using a nuclear protein extraction kit (Beyotime, China, P0028) according to the manufacturer’s protocol. The human lamin B and β-actin antibodies were used as the internal controls for protein loading, and relative expression levels were quantified using Quantity One software.

2.9. Lipid ROS Assay. Chondrocytes were incubated with 5 μM C11-BODIPY™ 381/393 (Thermo Fisher Scientific, USA) fluorescent probe in a serum-free medium for 30 min at 37°C in the dark and washed three times with PBS according to the modified protocol. The green and red fluorescence signals were observed under a fluorescence microscope (Nikon Eclipse Ti, Japan). The fluorescence intensity was quantified using Image Pro Plus 6.0 software.

2.10. Fe2+ Detection. The Fe2+ content of different groups was analyzed using a Mito-Ferrogreen Assay Kit (Dojindo, Shanghai, China) according to the manufacturer’s instructions. The Fe2+-positive cells were green under fluorescence microscopy (Nikon Eclipse Ti, Japan), and the fluorescence intensity was quantified using Image Pro Plus 6.0 software.

2.11. Si-RNA Transfection Analysis. The Nuclear factor erythroid 2-related factor 2 (Nrf2) siRNA sequence was purchased from Beyotime Biotechnology (Shanghai, China) and the siRNA sequences are as follows: Si-Nrf2#1: 5′-CATTGAGTGTTTCCTGATCTA-3′; Si-Nrf2#2: 5′-GGTTGAGCTACATGCTGTT-3′; Si-Nrf2#3: 5′-GAGGCAAGATATAGACTT-3′. Transfections were performed according to the manufacturer’s instructions. The group of chondrocytes transfected with an empty vector was used as the negative control.

2.12. Animal Experiments. In total, 25 male SD rats, weighing 150 to 200 g, were purchased from Cavens Experimental Animal Co. Ltd. (Changzhou, China). All rats were randomly divided into five groups: control, OA, OA+Erastin, OA+Erastin+TF3, and OA+Erastin+DFO. DFO, an effective iron chelator, has been used to inhibit ferroptosis in various degenerative disease models [33]. In an OA animal model, DFO delayed the progression of primary OA. Therefore, DFO was selected as a positive control for animal experimental treatment [34]. The OA model was successfully established by medial meniscus destabilization (DMM) surgery. TF3 (1 mg/kg), erastin (1 mg/kg), or DFO (1 mg/kg) were injected into the articular cavity twice a week, and the rats were sacrificed six weeks later. The progression of OA was evaluated using the Osteoarthritis Research Society International (OARSI) scored by two blinded investigators. The effects of TF3 and DFO for protein loading, and relative expression levels were quantified using Quantity One software.
treatments were measured by morphological analysis and magnetic resonance imaging (MRI) examination. The animal study proposal was approved by the Animal Care Committee of Nanjing Medical University. All animal experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People’s Republic of China.

2.13. MRI Examination. Six weeks after the model operation, cartilage damage was examined by MRI.

2.14. Immunohistochemical Staining and Histomorphometric Measurements. Tibial and femoral tissues were separated and fixed in 10% formalin, decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for 3 weeks after washing with water, and then dehydrated in graded alcohols. Specimens were embedded in paraffin and cut into 5 μm serial sections. 3 sections per rat were analyzed, and all sections were from medial femoral condyles. H2O2 (3%) and BSA (5%) were used to block endogenous peroxidase activity and nonspecific binding sites, respectively. The Gpx4 primary antibodies were incubated overnight at 4 °C. Next, the appropriate HRP-conjugated secondary antibody was added to the sections for incubation and counterstaining with haematoxylin at room temperature. Each glass slide was stained with HE and Masson’s staining according to the manufacturer’s instructions.

2.15. Statistical Analysis. Statistical analyses were performed using Prism8 (GraphPad Software, San Diego, CA, US). Unpaired Student’s t-test was used for two groups; one-way ANOVA was used for more than two groups, and the Mann–Whitney U test was used for ranked data analysis. All quoted p values were 2-tailed, and those less than 0.05 were considered statistically significant.

3. Results

3.1. The Expression of Gpx4 in Cultured Chondrocytes from OA Patients. We examined the expression of Gpx4 in cultured chondrocytes isolated from articular cartilage tissues derived from OA patients and trauma patients with femur fractures. The results showed that the mRNA and protein expression levels of Gpx4 were decreased in OA chondrocytes compared with chondrocytes from trauma patients (Figures 1(a) and 1(b)), suggesting that the ability of chondrocytes to clear ROS was largely compromised in OA.

3.2. TF3 Shows No Significant Cytotoxicity to Chondrocytes at Appropriate Concentrations. The molecular structure of TF3 was shown in Figure 2(a). To evaluate the dose effect of the ferroptosis activator erastin, cultured OA chondrocytes were incubated with five different concentrations of erastin (1, 2, 5, 10, and 20 μM) and the solvent DMSO as a control. As demonstrated in Figure 2(b), chondrocyte viability was decreased in a dose-dependent manner. Notably, when chondrocytes were treated with 5 μM erastin, chondrocyte ferroptosis was successfully induced with a reduced viability after 12 hrs. Therefore, a 5 μM concentration of erastin was used to induce ferroptosis in the subsequent experiments. Next, we used different concentrations of TF3 (5, 10, 15, 30, and 60 μM) to treat OA chondrocytes for 12 hrs or 24 hrs. The MTS results showed that TF3 did not significantly affect chondrocyte viability at different concentrations (Figures 2(c) and 2(d)), suggesting that TF3 had no significant cytotoxicity to culture chondrocytes at given concentrations.

3.3. TF3 Reverses Erastin-Induced Cell Viability in Cultured OA Chondrocytes. To evaluate the protective role of TF3, chondrocytes were pretreated with 15 μM or 30 μM TF3 for 2 hrs before 24 hrs of incubation with 5 μM erastin. Both concentrations of TF3 (15 and 30 μM) markedly rescued erastin-induced chondrocyte viability, with a more significant effect at a higher concentration of TF3, as shown in Figure 2(e), suggesting a protective role of TF3 in erastin-induced chondrocyte.

3.4. TF3 Inhibits the Erastin-Induced ROS Level in OA Chondrocytes. Next, we used different concentrations of erastin to induce ferroptosis in OA chondrocytes, used PI staining to visualize the chondrocyte ferroptosis and a
C11BODIPY fluorescent probe to detect intracellular ROS and lipid ROS levels, and examined ferroptosis-related protein expression by western blot. PI staining showed that chondrocyte ferroptosis was significantly promoted by erastin (Figures 3(a) and 3(b)). Both intracellular ROS and lipid ROS were accumulated in erastin-treated chondrocytes as reflected by the intensity of green fluorescence (Figures 3(c) and 3(d)). However, TF3 reduced the levels of intracellular ROS and lipid ROS and the number of PI-positive chondrocytes (Figures 3(a)–3(d)). Western blot indicated that erastin decreased ferroptosis-related protein expression, ferritin heavy chain 1 (FTH-1), and Gpx4 (Figures 3(e) and 3(f)). In addition, TF3 reversed the expression of FTH-1, Gpx4, and Scl7a11 (Figure 3(g)).

**Figure 2**: TF3 reverses erastin-induced chondrocyte viability. (a) Chemical structure diagram of TF3. (b) Chondrocytes were treated with different concentrations of erastin (1 μM, 2 μM, 5 μM, 10 μM, and 20 μM) for 24 hrs. (c, d) Chondrocytes were treated with different concentrations of TF3 for 12 hrs or 24 hrs. (e) Chondrocytes were pretreated with TF3 (15 μM/30 μM) for 2 hours and then stimulated with erastin (5 μM) for 24 hrs. The results are presented as the mean ± SD of three independent experiments, and statistical significance was determined by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. NC: negative control.
Figure 3: Continued.
Together, these observations indicated that TF3 inhibits chondrocyte ferroptosis by improving the Gpx4 expression suppressed by erastin.

3.5. TF3 Promotes Iron Metabolism in Cultured OA Chondrocytes. Abnormal iron metabolism is another contributor to ferroptosis, and iron deposits are found in OA [35]. Ferrogreen was used to detect the Fe\(^{2+}\) level. The results showed that Fe\(^{2+}\) was accumulated in chondrocytes treated with erastin. In contrast, TF3 reduced the accumulation as reflected by the intensity of green fluorescence (Figures 3(i) and 3(j)). In addition, Fe\(^{2+}\) was stored in FTH1, and FTH1 participated in iron metabolism progression. Western blot results showed that TF3 upregulated the expression of FTH1 in the erastin-treated chondrocytes (Figure 3(g)). Taken together, TF3 improves iron metabolism in OA chondrocytes.

3.6. TF3 Protects Chondrocytes from Ferroptosis via the Nrf2/Gpx4 Signaling Pathway. To further investigate molecular mechanisms for TF3 in protecting chondrocytes from ferroptosis, we detected change of the signaling pathway-related proteins. TF3 significantly increased Nrf2, Keap1, p-MEK1/2, and p-Erk1/2 expressions in the total cell lysate (Figures 4(a) and 4(b)). Next, we separated the nucleus component from cytoplasm and carried out western blot analysis. A significantly increased expression of Nrf2 was observed in the nucleus and the cytoplasm upon TF3 treatment (Figures 4(c) and 4(d)). Then, we knockdown Nrf2 expression by using small interfering RNA (si-RNA) and...
observed the effect of TF3 on chondrocyte ferroptosis. The effectiveness of knockdown was confirmed in Figure 5(a).

We observed that the combination treatment of erasin with TF3 significantly increased the PI-positive cell percentage, levels of lipid ROS, Fe^{2+} in mitochondria in the si-Nrf2 chondrocytes compared with the si-NC chondrocytes (Figures 5(b)–5(g)). On the contrary, the expression of ferroptosis-related protein (Slc7a11, Gpx4, FTH1, and HO-1) was markedly decreased in erastin+TF3 group in comparison with the erastin+TF3+si-NC group (Figures 5(h) and 5(i)). Collectively, these data suggested that the Nrf2/Gpx4 signaling pathway is involved in TF3-regulated chondrocyte ferroptosis.

3.7. TF3 Attenuates Cartilage Degradation and Increased Proteoglycans and Gpx4 Expression in a Rat OA Model. To further explore the role of TF3-regulated ferroptosis in vitro, we established a rat OA model. The gross morphological images of the rat’s knee were shown in Figure 7(a). In the OA group, the articular surface was rough and ulcerated. The degree of cartilage joint injuries was more serious in OA + erastin group, while the cartilage joint injuries were repaired in the OA + erastin+TF3 group to some extent.
Figure 5: Continued.
The MRI results illustrated that the degree of articular surface cartilage destruction in OA + erastin group was also more serious than that of in the OA group, while the degree of articular cartilage destruction was significantly alleviated in the TF3 treatment groups (Figure 7(b)). Furthermore, we also observed that cartilage damage was reversed after TF3 treatment, as showed by HE staining (Figure 7(c)) and OARSI score (Figure 7(d)). These observations suggested that articular cartilage damage might be repressed by TF3.

The proteoglycans in the cartilage were gradually lost as OA progresses. We used Masson’s staining to assess the changes of proteoglycans in cartilage. Intra-articular injection of 1 mg/kg TF3 significantly reversed the proteoglycans levels in the cartilage, as assessed in Figure 8(a). Immunohistochemistry staining showed that the number of Gpx4-positive chondrocytes was reduced in the OA + erastin group, but significantly increased in OA + erastin+TF3 group (Figures 8(b) and 8(c)). In summary, TF3 alleviates OA progression by Gpx4-mediated inhibition of chondrocyte ferroptosis in a rat OA model.

4. Discussion

In this study, we found that TF3 delayed the progression of OA and protected chondrocytes from ferroptosis via modulation of the Nrf2/Gpx4 signaling pathway. Currently, non-steroid anti-inflammatory drugs (NSAIDS) is prescribed for treatment of OA. While it affords some protection to ferroptosis, it has noticeable side effects. Researchers have reported drug-drug interactions resulting in liver damages [36]. In erastin-induced chondrocyte ferroptosis, TF3, at nontoxic concentrations, reversed cell viability in a dose-dependent manner, suggesting that TF3 may have the fewer
Figure 6: Continued.
side effects and plays a protective role in OA chondrocyte ferroptosis.

Erastin, a ferroptosis inducer, can reduce glutathione levels by directly inhibiting cystine/glutamate antiporter system Xc- activity and activating the ferroptotic response [37], increasing ROS and iron accumulation further inducing ferroptosis [38]. Thus, we chose erastin to induce chondrocyte ferroptosis. Lipid peroxidation and iron accumulation were key factors in ferroptosis. Gpx4, an antioxidant agent, was negatively correlated with lipid peroxidation and showed protective effect on ferroptosis. Studies have indicated that the expression of Gpx4 was decreased in synovial fluid from the patients with OA and rheumatoid arthritis (RA) [39, 40], which is consistent with our findings. Its inhibition blocks intracellular iron metabolism, resulting in lipid peroxidation products and ROS accumulation and thus accelerating ferroptosis progress [41]. Additionally, ROS is related to cartilage damage in OA [42]. Consistent with previous studies, the level of Gpx4 was decreased in the erastin-treated chondrocytes. In the presence of TF3, the decreased level of Gpx4 and lethal ROS accumulation were reversed in a concentration-dependent manner, suggesting the anti-liposome peroxidation ability of TF3.

Abnormal iron metabolism contributes to ferroptosis induced by the production of ROS from the Fenton reaction [35, 43]. Divalent metal transporter 1 (DMT1, also named Slc11a2) mediates the release of Fe2+ from the endosome into a labile iron pool in the cytoplasm [44]. Excess iron is stored in an iron storage protein complex including ferritin light chain (FTL) and ferritin heavy chain1 (FTH1) [45]. Increased iron uptake and reduced iron storage may contribute to iron overload during ferroptosis [46]. Consistently, our results showed that the level of Fe2+ was increased in the erastin-treated chondrocytes and reversed by addition of TF3. In addition, TF3 promoted FTH1 expression. These observations suggested that TF3 inhibits ferroptosis by promoting iron metabolism in OA chondrocytes.

The mechanism of ferroptosis has not been fully elucidated. Cystine-glutamate antiporter (System Xc-) [47, 48], coenzyme Q (CoQ) [49], and ASCL4-related pathways have been involved in ferroptosis [50–52]. Slc7a11, a subunit unique to system Xc, inhibits intracellular GSH depletion, iron-dependent lipid peroxidation and subsequent ferroptosis [53]. Our study showed that TF3 elevates the expression of Slc7a11, suggesting that Slc7a11 mediates TF3 anti-ferroptosis effect.

Recently, growing attention has been given to the role of the Nrf2 transcription factor in cartilage homeostasis [54]. Nrf2 is capable of regulating the basal and inducible expression of a plethora of antioxidant and detoxification enzymes, including CAT, SOD, Gpxs, heme-oxygenase1 (HO-1), NADPH, and quinone oxidoreductase1 (NQO1) [55, 56]. Pharmacological activation of Nrf2 or overexpression of Nrf2 [57] has been shown to limit IL-1β-induced reactive oxygen species generation and reduce the absorption of iron in chondrocytes, demonstrating the importance of Nrf2 activity on the antioxidant response in cartilage. We found that the MEK1/2, ERK1/2, and keap1/Nrf2/Gpx4 signaling pathways were activated in erastin-treated chondrocytes in the presence of TF3. Under normal conditions, the DGR region of Keap1 binds to the DLG and ETGE sequences of Nrf2, which stabilizes Nrf2 in the cytoplasm and induces Nrf2 ubiquitination and proteasome degradation [58]. Keap1 transforms its connection with Nrf2 by sensing changes in ROS, promoting Nrf2 accumulation binding with the promoter antioxidant response element (ARE) to induce downstream antioxidant proteases transcription and translation [59]. The increased ROS level was associated with the elevated Nrf2 expression, by which cells maintain oxidative stress balance [60]. These studies were
consistent with the observation that after the chondrocytes were stimulated by erastin, the expressions of Nrf2 in the nucleus and lipid ROS levels in chondrocytes were all markedly increased. After TF3 intervention, nucleus Nrf2 bound with the promoter ARE to induce Gpx4 expression, further scavenging lipid ROS. Further, knockdown of Nrf2 resulted in decreased expression of downstream targets (Slc7a11, Gpx4, FTH1, and HO-1), and TF3 did not completely reverse Gpx4 expression and erastin-induced chondrocyte ferroptosis in Nrf2 knockdown cells. In further support, application of the Gpx4 inhibitor RSL3 [61] caused similar results to that of Nrf2 knockdown, such as elevated lipid peroxidation, decreased cell viability, and thus increased ferroptosis. However, when chondrocytes were pretreated with RSL3, TF3 could not reverse chondrocyte ferroptosis, strongly implicating that the protective effects of TF3 on cell viability were mediated via activation of Gpx4, which protects against ferroptosis. Thus, these results suggested that
the Nrf2/Gpx4-related pathway is a mediator of the protective effects of TF3 in OA chondrocytes.

Delaying articular cartilage degeneration was the key intervention method for OA treatment [62]. Systemic administration of DFO reduces cartilage lesion development in the OA model [34]. Our animal experiments results showed that TF3 could alleviate the degeneration of OA cartilage, which was manifested by a lower OARSI score and lower degree of articular cartilage destruction. Meanwhile, TF3 notably upregulated the expression of proteoglycans in OA chondrocytes.
and antiferroptosis protein Gpx4. These in vivo results indicated the protective effect of TF3 on OA was similar to that of DFO.

5. Conclusions
In summary, we found that TF3 protects chondrocytes against erastin-induced ferroptosis via the Nrf2/Gpx4 signaling pathway activation, suggesting that TF3 might be a novel and promising therapeutic option for OA (graphical abstracts).

Abbreviations

OA: Osteoarthritis  
TCA: Tricarboxylic acid cycle  
AA: Ascorbic acid  
ROS: Reactive oxygen species  
MDA: Malondialdehyde  
SOD: Peroxide dismutase  
Gpx4: Glutathione peroxidase 4  
GSH: Glutathione  
TF3: Theaflavin-3,3′-digallate  
BMMs: Bone marrow-derived macrophages  
DFO: Deferoxamine  
OARSI: Osteoarthritis research society international  
DMEM: Dulbecco’s modified Eagle’s medium  
AA: Ascorbic acid  
RIPA: Radioimmunoprecipitation assay buffer  
PVDF: Polyvinylidene fluoride  
MRI: Magnetic resonance imaging  
EDTA: Ethylenediaminetetraacetic acid  
DMM: Medial meniscus destabilization  
Nrf2: Nuclear factor erythroid 2-related factor 2  
NSAIDs: Nonsteroid anti-inflammatory drugs  
DMT1: Divalent metal transporter 1  
FTL: Ferritin heavy chain  
System Xc–: Cystine-glutamate antitransporter  
COQ: Coenzyme Q  
Slc7a11: Light chain subunit of the cystine/glutamate antitransporter  
NQO1: NADPH quinone oxidoreductase 1  
HO-1: Heme-oxygenase 1  
ARE: Antioxidant response element.

Data Availability
The datasets used in the present study are available from the corresponding author on reasonable request.

Ethical Approval
The informed consent form was approved by the Nanjing Medical University Review Board (the file number is [2017] KY035-01).

Consent
All participants have signed the informed consent form prior to their participation in the study.

Conflicts of Interest
The authors declare that they are free from conflict of interest in presenting it.

Authors’ Contributions
YW contributed to the conception and design of the study. NS, XC, YYY, and YGR carried out the principal experiments. XC and ZBJ completed the acquisition or preparation of clinical samples. ZGY, WLL, JSJ, XNW, and ZRX contributed to the analysis and interpretation of the data. XC contributed to the drafting of the article. YW contributed to the critical revision of important intellectual content. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (81171680 to Y.W.), the Science and Technology Support Program of Jiangsu Province (BE2015632 to Y.W.), the Changzhou Science and Technology Bureau (ZD202217 to Y.W., CJ20180057 to S.N., and WZ202204 to C.X.), the Natural Science Foundation of the Jiangsu for Youth (BK20180182 to S.N.), China Postdoctoral Science Foundation (2019M651898 to S.N.), Changzhou No. 2. People’s Hospital Foundation (2022 K004 to C.X.). We want to thank all the patients who participated in our study and Professors Xianju Zhou, Dawei Li, and Stephen Rudnik for giving suggestions.

Supplementary Materials
Table S1: the key information of all antibodies used in our study and the graphical abstracts are available in supplementary files. (Supplementary Materials)

References


Oxidative Medicine and Cellular Longevity


